每年出版 4 期
ISSN 打印: 0731-8898
ISSN 在线: 2162-6537
Indexed in
Modulation of c-Kit/SCF Pathway Leads to Alterations in Topoisomerase-I Activity in Small Cell Lung Cancer
摘要
Small cell lung cancer (SCLC) is an aggressive type of lung cancer, for which cytotoxic chemotherapy appears to have reached its maximal efficacy. This neoplasm is characterized by the overexpression of several receptor tyrosine kinases (RTKs), especially c-Kit. The ligand for c-Kit is stem cell factor (SCF). In SCLC, SCF can influence c-Kit activation by autocrine or paracrine mechanisms. We have recently shown that the c-Kit/SCF pathway is operational in SCLC and can be inhibited by Glivec (STI571). Because the inhibition of topoisomerase-I (topo-I) is one approach used to treat SCLC, we determined the effects of c-Kit/SCF signaling on topo-I activity. A unique phosphorylation of c-Kit on amino acid 823 and amino acid 703 was identified with the SCF stimulation of H526 cells. We demonstrate that with SCF stimulation over 16 hours (dose response 0−100 ng/mL) in H526 SCLC cells (c-Kit positive, SCF responsive), a decrease in topo-I activity was observed, whereas in H82 SCLC cells (c-Kit negative, SCF unresponsive) there was no modulation of topo-I activity by SCF. Using STI571 (5 μM, 16 hours) to inhibit the c-Kit pathway following stimulation with SCF (100 ng/mL), an upregulation of topo-I activity was observed in H526 cells but not in H82 cells. Performing viability assays, we show that STI571 in combination with topo-I inhibition by camptothecin or SN38, the active metabolite of irinotecan, can cooperatively inhibit H526 cell viability (but not H82 cell viability) for 72 hours. We also show that STI571 does not directly inhibit topo-I activity in SCLC. The combination of STI571 with topo-I inhibition could provide a useful combination in the treatment of SCLC.
-
DiNitto J. P., Deshmukh G. D., Zhang Y., Jacques S. L., Coli R., Worrall J. W., Diehl W., English J. M., Wu J. C., Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance, Journal of Biochemistry, 147, 4, 2010. Crossref
-
Johnson Faye M., Krug Lee M., Tran Hai T., Shoaf Stephanie, Prieto Victor G., Tamboli Pheroze, Peeples Beverly, Patel Jyoti, Glisson Bonnie S., Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma, Cancer, 106, 2, 2006. Crossref
-
Locascio Lauren E., Donoghue Daniel J., KIDs rule: regulatory phosphorylation of RTKs, Trends in Biochemical Sciences, 38, 2, 2013. Crossref
-
Ferguson Benjamin D., Liu Ren, Rolle Cleo E., Tan Yi-Hung Carol, Krasnoperov Valery, Kanteti Rajani, Tretiakova Maria S., Cervantes Gustavo M., Hasina Rifat, Hseu Robyn D., Iafrate A. John, Karrison Theodore, Ferguson Mark K., Husain Aliya N., Faoro Leonardo, Vokes Everett E., Gill Parkash S., Salgia Ravi, Miller Todd W., The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target, PLoS ONE, 8, 7, 2013. Crossref
-
Hu Anling, Huang Juan, Li Shiyue, Gao Yang, Wu Li, Deng Jiang, Liu Jie, Gong Qihai, Li Lisheng, Xu Shangfu, Involvement of stromal cell-derived factor-1α (SDF-1α), stem cell factor (SCF), fractalkine (FKN) and VEGF in TSG protection against intimal hyperplasia in rat balloon injury, Biomedicine & Pharmacotherapy, 110, 2019. Crossref
-
Cagle Philip T., Jagirdar Jaishree, Popper Helmut H., Molecular Genetics of Lung and Pleural Neoplasms, in Dail and Hammar’s Pulmonary Pathology, 2008. Crossref
-
Allen Timothy Craig, Sienko Anna, Cagle Philip T., Response to Conventional Therapy and Targeted Molecular Therapy, in Molecular Pathology of Lung Diseases, 1, 2008. Crossref
-
Pham Duc Daniel M., Guhan Samantha, Tsao Hensin, KIT and Melanoma: Biological Insights and Clinical Implications, Yonsei Medical Journal, 61, 7, 2020. Crossref
-
Levy A., Malouf G.G., Besse B., Massard C., Soria J.-C., Thérapies moléculaires ciblées dans le cancer du poumon à petites cellules, Bulletin du Cancer, 97, 5, 2010. Crossref
-
Foster Brittni M., Langsten Kendall L., Mansour Ammar, Shi Lihong, Kerr Bethany A., Tissue distribution of stem cell factor in adults, Experimental and Molecular Pathology, 122, 2021. Crossref
-
Shraim Ala’a S., Hunaiti Abdelrahim, Awidi Abdalla, Alshaer Walhan, Ababneh Nidaa A., Abu-Irmaileh Bashaer, Odeh Fadwa, Ismail Said, Developing and Characterization of Chemically Modified RNA Aptamers for Targeting Wild Type and Mutated c-KIT Receptor Tyrosine Kinases, Journal of Medicinal Chemistry, 63, 5, 2020. Crossref
-
Huguet Florence, Giocanti Nicole, Hennequin Christophe, Croisy Martine, Touboul Emmanuel, Favaudon Vincent, Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells, Molecular Cancer Therapeutics, 7, 2, 2008. Crossref
-
Chen Tingchao, Burke Kathleen A., Zhan Yuxia, Wang Xingchao, Shibata Darryl, Zhao Yi, IL-12 Facilitates Both the Recovery of Endogenous Hematopoiesis and the Engraftment of Stem Cells after Ionizing Radiation, Experimental Hematology, 35, 2, 2007. Crossref
-
Rager Taylor, Eckburg Adam, Patel Meet, Qiu Rong, Gantiwala Shahina, Dovalovsky Katrina, Fan Kelly, Lam Katie, Roesler Claire, Rastogi Aayush, Gautam Shruti, Dube Namrata, Morgan Bridget, Nasifuzzaman S M, Ramaswami Dhruv, Gnanasekar Varun, Smith Jeffrey, Merchant Aftab, Puri Neelu, Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies, Cancers, 14, 15, 2022. Crossref